Dow Drops More Than 1%; Nio Stock Declines Following Q2 Earnings Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 02 2025
0mins
Source: Benzinga
U.S. Stock Market Performance: U.S. stocks declined, with the Dow Jones falling over 1%, while the NASDAQ and S&P 500 also experienced significant drops. Notable movements included a 2% decrease in NIO shares following disappointing quarterly results, despite a year-over-year revenue increase.
Sector and Commodity Updates: Consumer staples saw a slight increase, while information technology stocks fell. In commodities, oil and gold prices rose, and European and Asian markets mostly closed lower, reflecting a broader trend of declining equities globally.
Analyst Views on UTHR
Wall Street analysts forecast UTHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UTHR is 520.00 USD with a low forecast of 423.00 USD and a high forecast of 600.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
9 Buy
4 Hold
0 Sell
Moderate Buy
Current: 471.990
Low
423.00
Averages
520.00
High
600.00
Current: 471.990
Low
423.00
Averages
520.00
High
600.00
About UTHR
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
